Virological suppression in children and adolescents is not influenced by genotyping, but depends on optimal adherence to antiretroviral therapy
TLDR
Despite the use of genotyping tests in guidance of a more effective antiretroviral regimen, poor adherence to ART seems to be the main determinant of low virological suppression rate for children and adolescents, in Salvador, Brazil.Abstract:
Objective To evaluate the virological outcomes in children and adolescents infected with HIV-1 in Salvador, Bahia according to genotyping results. Methods We retrospectively evaluated the rates of virological suppression of children and adolescents submitted to HIV-1 genotyping test from January/2008 to December/2012. The participants were followed in the two referral centers for pediatric AIDS care, in Salvador, Brazil. Resistance mutations, drug sensitivity profiles, and viral subtypes were analyzed using the Stanford HIV-1 Drug Resistance Database. Adherence was estimated by drugs withdrawal at pharmacies of the two sites. Results 101 subjects were included: 35 (34.6%) were drug-naive, and the remaining 66 were failing ART. In drug-naive group, 3 (8.6%), presented with NNRTIs resistance mutations, along with polymorphic mutations to PIs in most (82.8%) of them. Among the failing therapy group, we detected a high frequency (89.4%) of resistance mutations to PIs, NRTI (84.8%), and NNRTI (59.1%). Virological suppression after introduction/modification of genotyping-guided ART was achieved only for patients (53.1%) with drug withdrawal over 95%. Main detected HIV-1 subtypes were B (67.3%), F (7.9), C (1.9%), and recombinant forms (22.9%). Conclusions Despite the use of genotyping tests in guidance of a more effective antiretroviral regimen, poor adherence to ART seems to be the main determinant of low virological suppression rate for children and adolescents, in Salvador, Brazil.read more
Citations
More filters
Journal ArticleDOI
Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda.
Sarah Nabukeera,Joseph Kagaayi,Fredrick Makumbi,Henry Mugerwa,Joseph K. B. Matovu,Joseph K. B. Matovu +5 more
TL;DR: In this paper, the authors determined the factors associated with virological non-suppression among children living with HIV receiving ART at a peri-urban HIV care clinic in Kampala, Uganda.
Journal ArticleDOI
Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment
Vinie Kouamou,Bhavini Varyani,Tinei Shamu,Tichaona Mapangisana,Cleophas Chimbetete,Tinashe Mudzviti,Justen Manasa,David Katzenstein +7 more
TL;DR: These 74 adolescents and young adults failing 1st line ART demonstrated high levels (97%) of DRMs despite enhanced adherence counseling, and switching to new NRTIs in 2nd line improved VS.
Journal ArticleDOI
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
Vinie Kouamou,Justen Manasa,David Katzenstein,Alan M McGregor,Chiratidzo E. Ndhlovu,Azure T Makadzange +5 more
TL;DR: In 1st-line failure, implementation of TLD for many adolescents and young adults on long-term ART may require additional active drug(s) and drug resistance surveillance and susceptibility scores may inform strategies for the implementation ofTLD.
Journal ArticleDOI
HIV‐1 subtype frequency in Northeast Brazil: A systematic review and meta‐analysis
Clevson Pessoa da Costa,Jessyca Kalynne Farias Rodrigues,Viviane Martha Santos de Morais,Viviane Martha Santos de Morais,Carlos Alberto das Neves Andrade,Patrícia Areias Feitosa Neves,Kledoaldo Lima +6 more
TL;DR: Although subtype B is predominant in Brazil, a large frequency of non‐B subtypes has also been found, which may have consequences for response to antiretroviral therapy, disease progression, and transmission.
Journal ArticleDOI
Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial)
E. Abe,Lambert Assoumou,Pierre de Truchis,Karine Amat,Séverine Gibowski,Guillaume Gras,Jonathan Bellet,Juliette Saillard,Christine Katlama,Dominique Costagliola,Pierre-Marie Girard,Roland Landman,Roland Landman,Jean-Claude Alvarez +13 more
TL;DR: Few data are available on plasma concentrations of antiretroviral therapy (ARV) during intermittent treatment.
References
More filters
Journal ArticleDOI
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy
TL;DR: Results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual.
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
Martin S. Hirsch,Scott M. Hammer,Victoria A. Johnson,Daniel R. Kuritzkes,Clive Loveday,John W. Mellors,Bonaventura Clotet,Brian Conway,Lisa M. Demeter,Stefano Vella,Donna M. Jacobsen,Douglas D. Richman +11 more
TL;DR: Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings, and resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women.
Journal ArticleDOI
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
Jacques Durant,P. H. Clevenbergh,Philippe Halfon,P. Delgiudice,S. Porsin,P. Simonet,N Montagne,Charles A. Boucher,J. M. Schapiro,Pierre Dellamonica +9 more
TL;DR: Genotypic-resistance testing is found to have a significant benefit on the virological response when choosing a therapeutic alternative for HIV-1-infected patients in whom combination therapy was not successful.
Journal ArticleDOI
Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
Martin S. Hirsch,Françoise Brun-Vézinet,Richard T. D'Aquila,Scott M. Hammer,Victoria A. Johnson,Daniel R. Kuritzkes,Clive Loveday,John W. Mellors,Bonaventura Clotet,Brian Conway,Lisa M. Demeter,Stefano Vella,Donna M. Jacobsen,Douglas D. Richman +13 more
TL;DR: The International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing as discussed by the authors.
Journal ArticleDOI
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
John D. Baxter,Douglas L. Mayers,Deborah Wentworth,James D. Neaton,Marie L. Hoover,Mark A. Winters,Sharon B. Mannheimer,Melanie A. Thompson,Donald I. Abrams,Barbara Brizz,John P. A. Ioannidis,John P. A. Ioannidis,Thomas C. Merigan +12 more
TL;DR: In this paper, the short-term effects of using genotypic antiretroviral resistance testing (GART) with expert advice in the management of patients failing on a protease inhibitor and two nucleoside reverse transcriptase inhibitors were determined.